Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAUREN GLUCK

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1033524780
CMS profile
5701792
Location
BRONX, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$22,474.83

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $17,770.00 7
Food and Beverage $4,014.15 66
Travel and Lodging $690.68 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
TG Therapeutics, Inc. $7,782.82 14
Genentech USA, Inc. $6,924.87 12
Alexion Pharmaceuticals, Inc. $3,637.32 4
E.R. Squibb & Sons, L.L.C. $1,280.00 1
EMD Serono, Inc. $1,164.25 13
Novartis Pharmaceuticals Corporation $680.82 15
GENZYME CORPORATION $276.22 3
Amgen Inc. $240.11 6
Biogen, Inc. $177.83 4
Genentech, Inc. $157.47 2
ANI Pharmaceuticals, Inc. $153.12 2

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAUREN GLUCK

NPI 1033524780 · CMS profile ID 5701792

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BRONX, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033524780?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAUREN GLUCK, NPI 1033524780, CMS profile ID 5701792. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033524780?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LAUREN GLUCK, NPI 1033524780, CMS profile ID 5701792. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033524780?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LAUREN GLUCK, NPI 1033524780, CMS profile ID 5701792, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 76 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1033524780?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $22,474.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $17.3912/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111584836 CMS
TG Therapeutics, Inc. $500.0012/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887890 CMS
EMD Serono, Inc. $121.6912/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120275936 CMS
E.R. Squibb & Sons, L.L.C. $1,280.0012/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101216678 CMS
Novartis Pharmaceuticals Corporation $31.1411/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936839 CMS
TG Therapeutics, Inc. $27.7311/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887858 CMS
EMD Serono, Inc. $97.9911/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120274068 CMS
EMD Serono, Inc. $43.0410/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120266307 CMS
Novartis Pharmaceuticals Corporation $121.2610/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936835 CMS
ANI Pharmaceuticals, Inc. $28.1810/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091147388 CMS
EMD Serono, Inc. $94.2410/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120266403 CMS
EMD Serono, Inc. $21.2810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120268376 CMS
TG Therapeutics, Inc. $2,700.0009/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887792 CMS
EMD Serono, Inc. $14.0009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120259176 CMS
EMD Serono, Inc. $115.6509/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120259182 CMS
Genentech USA, Inc. $28.0709/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133051990 CMS
Genentech USA, Inc. $146.2509/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133051994 CMS
TG Therapeutics, Inc. $76.4709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887880 CMS
TG Therapeutics, Inc. $57.2909/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887888 CMS
Novartis Pharmaceuticals Corporation $24.8609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936829 CMS
Genentech USA, Inc. $110.1709/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133051998 CMS
Genentech USA, Inc. $5,690.0009/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052003 CMS
Genentech USA, Inc. $228.9509/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052012 CMS
Genentech USA, Inc. $83.1009/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052016 CMS
Genentech USA, Inc. $248.8509/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052020 CMS
Genentech USA, Inc. $68.9109/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052024 CMS
Genentech USA, Inc. $212.8809/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052028 CMS
Genentech USA, Inc. $52.7209/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052032 CMS
EMD Serono, Inc. $122.9408/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120254569 CMS
Alexion Pharmaceuticals, Inc. $33.5908/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093985868 CMS
TG Therapeutics, Inc. $2,025.0008/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887790 CMS
TG Therapeutics, Inc. $125.0008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887822 CMS
Novartis Pharmaceuticals Corporation $25.6608/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936827 CMS
Amgen Inc. $17.7308/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111584834 CMS
Novartis Pharmaceuticals Corporation $26.5907/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936825 CMS
TG Therapeutics, Inc. $24.4007/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887776 CMS
GENZYME CORPORATION $125.0007/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139881019 CMS
EMD Serono, Inc. $36.9306/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120252170 CMS
Amgen Inc. $16.5706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111584832 CMS
EMD Serono, Inc. $133.2206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120250673 CMS
Novartis Pharmaceuticals Corporation $93.6106/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936823 CMS
TG Therapeutics, Inc. $23.7405/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887730 CMS
Amgen Inc. $23.8705/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111584830 CMS
Genentech, Inc. $130.3305/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133052040 CMS
Genentech USA, Inc. $13.9505/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133051988 CMS
Novartis Pharmaceuticals Corporation $14.2205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936813 CMS
TG Therapeutics, Inc. $125.0005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887802 CMS
Biogen, Inc. $29.5105/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104859836 CMS
Novartis Pharmaceuticals Corporation $23.4005/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936815 CMS
Novartis Pharmaceuticals Corporation $7.6205/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086936817 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $788.13 12
PY2020 $342.07 9
PY2021 $1,947.09 22
PY2022 $13,765.85 47
PY2023 $14,311.68 68
PY2024 $22,474.83 76
PY2025 $26,877.29 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $57,067.90 12
PY2024 Principal investigator $56,970.49 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $1,020.00 12/17/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226080985
Principal investigator 1 Novartis Pharmaceuticals Corporation $102.60 10/28/2025 Covered Recipient Teaching Hospital
Montefiore Medical Center
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190297288
Principal investigator 1 GENZYME CORPORATION $135.00 10/14/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137891
Principal investigator 1 GENZYME CORPORATION $4,670.00 09/22/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137872
Principal investigator 1 GENZYME CORPORATION $2,635.00 09/15/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137866
Principal investigator 1 GENZYME CORPORATION $135.00 09/03/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137857
Principal investigator 1 GENZYME CORPORATION $135.00 09/03/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137869
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,168.75 05/13/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190297721
Principal investigator 1 GENZYME CORPORATION $1,435.00 04/28/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137782
Principal investigator 1 GENZYME CORPORATION $3,200.00 04/28/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137786
Principal investigator 1 GENZYME CORPORATION $31,670.00 04/14/2025 Non-covered Recipient Entity
Biomedical Research Alliance Of New York LLC
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226137779
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,761.55 01/31/2025 Covered Recipient Teaching Hospital
Montefiore Medical Center
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190296293